Dual-drug delivery system based on in situ gel-forming nanosuspension of forskolin to enhance antiglaucoma efficacy

AAPS PharmSciTech

Volumn 11, Issue 1, 2010, Pages 322-335

  Gupta, Saurabh ^a   Samanta, Malay K ^a   Raichur, Ashok M ^b  

^a JSS COLLEGE OF PHARMACY   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Forskolin; Glaucoma; Nanocrystal; Ocular drug delivery; Sol gel techniques

Indexed keywords

DEXAMETHASONE; FORSKOLIN; NANOPARTICLE; POLOXAMER; POLYCARBOPHIL;

ANIMAL EXPERIMENT; ANTIGLAUCOMA ACTIVITY; ARTICLE; CONTROLLED DRUG RELEASE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EYE IRRITATION; GELATION; HYDROGEL; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; NONHUMAN; PARTICLE SIZE; PH; PHASE TRANSITION; PRIORITY JOURNAL; ROOM TEMPERATURE; SHEAR STRESS; SURFACE PROPERTY; SUSPENSION; VISCOSITY;

ACRYLIC RESINS; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; EYE; FORSKOLIN; GELS; GLAUCOMA; MALE; POLOXAMER; RABBITS; SOLUBILITY; TEMPERATURE;

EID: 77950918063     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9388-x     Document Type: Article

References (42)

1. RN Weinreb PT Khaw 2004 Primary open-angle glaucoma Lancet 363 1711 20 10.1016/S0140-6736(04)16257-0 15158634 (Pubitemid 38670330)
2. HA Quigley AT Broman 2006 The number of people with glaucoma worldwide in 2010 and 2020 Br J Ophthalmol 90 262 7 10.1136/bjo.2005.081224 1:STN:280:DC%2BD28%2FpvFOjsA%3D%3D 16488940 (Pubitemid 43325451)
3. NL Burstein ML Sears 1984 Aqueous flow in human eyes is reduced by forskolin a potent adenylate cyclase activator Exp Eye Res 39 745 9 10.1016/0014-4835(84)90073-3 1:CAS:528:DyaL2MXptVWhtw%3D%3D 6542866 (Pubitemid 15199831)
4. BR Smith RN Gaster 1984 Forskolin a potent adenylate cyclase activator lowers rabbit IOP Arch Ophthalmol 102 146 8 1:CAS:528:DyaL2cXps1KksQ%3D%3D 6538408
5. J Caprioli M Sears 1983 Forskolin lowers intraocular pressure in rabbits, monkeys, and man Lancet 30 958 60 10.1016/S0140-6736(83)92084-6
6. C Seto S Eguchi M Araie S Matsumoto M Takase 1986 Acute effect of topical forskolin on aqueous humor dynamics in man Jpn J Ophthalmol 30 238 44 1:CAS:528:DyaL2sXktl2nug%3D%3D 3784136
7. J Caprioli M Sears 1984 Combined effect of forskolin and acetazolamide on IOP and aqueous flow in rabbit eye Exp Eye Res 39 47 50 10.1016/0014-4835(84) 90113-1 1:CAS:528:DyaL2cXls1elur4%3D 6541150 (Pubitemid 14068011)
8. Shah NH, Phuapradit W, Zhang YE, Sandhu H, Zhang L, Malick AW. In: Augsburger LA, Hoag SW, editors. Approaches for improving bioavailability of poorly soluble drugs. 3rd ed. London: Informa Healthcare; 2008. p. 62. Rational design and formulation; vol 2.
9. E Merisko-Liversidge GG Liversidge ER Cooper 2003 Nanosizing: a formulation approach for poorly-water-soluble compounds Eur J Pharm Sci 18 113 20 10.1016/S0928-0987(02)00251-8 1:CAS:528:DC%2BD3sXht1Kltrg%3D 12594003 (Pubitemid 36184748)
10. WL Chiou S Riegelman 1971 Pharmaceutical applications of solid dispersion systems J Pharm Sci 60 1281 302 10.1002/jps.2600600902 1:STN:280: DyaE3M3otFersQ%3D%3D 4935981
11. ON Pozharitskaya VA Vainshtein LF Strelkova NA Kalinina 1999 Study of mechanism of dissolution of nifedipine from solid dispersion system with Q10 polyethylene glycol Farmatsiia-Moskva 2 18 20
12. C Leuner J Dressman 2000 Improving drug solubility for oral delivery using solid dispersions Eur J Pharm Biopharm 50 47 60 10.1016/S0939-6411(00) 00076-X 1:CAS:528:DC%2BD3cXjslyju7c%3D 10840192 (Pubitemid 30326688)
13. R Gaudana J Jwala SHS Boddu AK Mitra 2009 Recent perspectives in ocular drug delivery Pharm Res 26 5 1197 216 10.1007/s11095-008-9694-0 1:CAS:528:DC%2BD1MXjvV2ksbw%3D 18758924
14. VHL Lee 1990 Review: new directions in the optimization of ocular drug delivery J Ocul Pharmacol 6 157 64 10.1089/jop.1990.6.157 1:STN:280: DyaK3czmvFWquw%3D%3D 2203851
15. R Gurny 1981 Preliminary study of prolonged acting drug delivery system for the treatment of glaucoma Pharm Acta Helv 56 130 2 1:CAS:528: DyaL38XptFKjsg%3D%3D 7255499
16. B Srividya RM Cardoza PD Amin 2001 Sustained ophthalmic delivery of ofloxacin from a pH-triggered in situ gelling system J Control Release 73 205 11 10.1016/S0168-3659(01)00279-6 1:CAS:528:DC%2BD3MXksVSqtbY%3D 11516498 (Pubitemid 32539249)
17. SC Miller MD Donovan 1982 Effect of poloxamer 407 gel in the miotic activity of pilocarpine nitrate in rabbits Int J Pharm 12 147 52 10.1016/0378-5173(82)90114-4 1:CAS:528:DyaL3sXit1ajtQ%3D%3D (Pubitemid 12037338)
18. M Vadnere G Amidon S Lendenbaum JL Haslam 1984 Thermodynamic studies on the gel-sol transition of some pluronic polyols Int J Pharm 22 207 18 10.1016/0378-5173(84)90022-X 1:CAS:528:DyaL2MXhvFSqsLs%3D (Pubitemid 15187772)
19. CW Spancake AK Mitra DO Klidsig 1989 Kinetics of aspirin hydrolysis in aqueous solutions and gels of poloxamines (tetronic 1508) influence of micro-environment Int J Pharm 57 163 8 10.1016/0378-5173(89)90305-0 (Pubitemid 20011840)
20. A Rozier C Manuel J Groove B Plazonet 1989 Gelrite: a novel ion activated in situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol Int J Pharm 57 163 8 10.1016/0378-5173(89)90305-0 1:CAS:528: DyaK3cXhtVClurc%3D (Pubitemid 20011840)
21. Z Liu J Li S Nie H Liu P Ding W Pan 2006 Study of an alginate/HPMC based in situ gelling ophthalmic delivery system for gatifloxacin Int J Pharm 315 12 7 10.1016/j.ijpharm.2006.01.029 1:CAS:528:DC%2BD28XksFyiu7o%3D 16616442
22. S Cohen E Lobel A Trevgoda Y Peled 1997 A novel in situ forming ophthalmic drug delivery system from alginates undergoing gelation in the eye J Control Release 44 201 8 10.1016/S0168-3659(96)01523-4 1:CAS:528: DyaK28XmvFeiu7o%3D (Pubitemid 27039116)
23. The Lubrizol Corporation. Wickliffe, Ohio, USA: Pharmaceutical ingredients. Online. 2008. http://www.lubrizol.com/pharmaceutical/products/ Noveon AA-1Polycarbophil.html.
24. AH El-Kamel 2002 In vitro and in vivo evaluation of pluronic F127 based ocular delivery system for timolol maleate Int J Pharm 241 47 55 10.1016/S0378-5173(02)00234-X 1:CAS:528:DC%2BD38XkslShurY%3D 12086720 (Pubitemid 34667065)
25. SD Desai J Blanchard 1998 In vitro evaluation of pluronic F127 based controlled release ocular delivery systems for pilocarpine J Pharm Sci 87 226 30 10.1021/js970090e 1:CAS:528:DyaK1cXjsVKjsg%3D%3D 9519158 (Pubitemid 28081333)
26. HR Lin KC Sung 2000 Carbopol/pluronic phase change solutions for ophthalmic drug delivery J Control Release 69 379 88 10.1016/S0168-3659(00) 00329-1 1:CAS:528:DC%2BD3cXotlart7s%3D 11102678
27. Gupta S, Samanta MK. Design and evaluation of thermoreversible in situ gelling system of forskolin for the treatment of glaucoma. Pharm Dev Tech 2009. doi: 10.1080/10837450903262033.
28. Staff OECD. OECD guidelines for the testing of chemicals. Fourteenth addendum. Paris: OECD; 2002.
29. D Small J Hevy D Tang-Liu 2000 Comparison of tear sampling techniques for pharmacokinetic analysis: ofloxacin concentrations in rabbit tears after sampling with schirmer tear strips, capillary tubes or surgical sponges J Ocul Pharmcol Ther 16 439 46 10.1089/jop.2000.16.439 1:CAS:528:DC%2BD3cXotFOjtbo%3D
30. IH Pang H Moll MA Mclaughlin PA Knepper LD Santis DL Epstein, et al. 2001 Ocular hypotensive and aqueous outflow-enhancing effects of AL-3037A (sodium ferri ethylenediaminetetraacetate) Exp Eye Res 73 815 25 10.1006/exer.2001.1087 1:CAS:528:DC%2BD38XhsVCitL0%3D 11846512 (Pubitemid 34112107)
31. PA Knepper JA Collins R Frederick 1985 Effects of dexamethasone, progesterone and testosterone on IOP and GAGs in the rabbit eye Invest Ophthalmol Vis Sci 26 1093 100 1:CAS:528:DyaL2MXltFKmtr4%3D 3926712
32. IP Kaur M Singh M Kanwar 2000 Formulation and evaluation of ophthalmic preparations of acetazolamide Int J Pharm 199 119 27 10.1016/S0378-5173(00) 00359-8 1:CAS:528:DC%2BD3cXjtVWqsro%3D 10802405 (Pubitemid 30236183)
33. JS Friedenwald 1937 Contribution to the theory and practice of tonometry Am J Ophthalmol 20 985 1024
34. WM Grant 1950 Tonographic method for measuring the facility and rate of aqueous flow in human eye Arch Ophthalmol 44 204 14 1:STN:280: DyaG3c%2FktlejsQ%3D%3D
35. J Lee 2003 Drug nano and microparticles processed into solid dosage forms: physical properties J Pharm Sci 92 10 2057 68 10.1002/jps.10471 1:CAS:528:DC%2BD3sXnvFOms7g%3D 14502544 (Pubitemid 37175635)
36. SC Miller BR Drabik 1984 Rheological properties of poloxamer vehicles Int J Pharm 18 269 76 10.1016/0378-5173(84)90142-X 1:CAS:528:DyaL2cXhvVSjtrw%3D (Pubitemid 14190777)
37. Lamberts DW, Potter DE. Clinical ophthalmic pharmacology. UK: Little Brown; 1987.
38. Gupta SK, Uppal RK, Agnihotri S, Jain N. Need for monitoring strict quality control measures in ophthalmic preparations. East Pharmacist. 1986; 43-8.
39. Lee VHL. Precorneal, corneal and postcorneal factors. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker; 1993. p. 59-81.
40. JL Greaves CG Wilson NR Galloway 1991 A comparison of the precorneal residence of an artificial tear preparation in patients with keratoconjunctivitis sicca and in normal volunteer subjects using gamma scintigraphy Acta Ophthalmol 69 432 6 10.1111/j.1755-3768.1991.tb02018.x 1:STN:280:DyaK38%2FoslKgsw%3D%3D
41. PA Knepper M Breen HG Weinstein JL Blacik 1978 Intraocular pressure and glycosaminoglycan distribution in the rabbit eye, effect of age and dexamethasone Exp Eye Res 27 567 75 10.1016/0014-4835(78)90141-0 1:CAS:528:DyaE1MXjsVeqtA%3D%3D 720430 (Pubitemid 9062844)
42. MF Saettone P Chetoni R Cerbai G Mazzanti L Braghiroli 1986 Evaluation of ocular permeation enhancer: in vitro effects on corneal transport of four b-blockers, and in vitro in vivo toxic activity Int J Pharm 142 103 13 10.1016/0378-5173(96)04663-7